- Home
- SPFI vs MYGN Comparison
SPFI vs MYGN Comparison
Compare SPFI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- MYGN
- Stock Information
- Founded
- SPFI 1941
- MYGN 1991
- Country
- SPFI United States
- MYGN United States
- Employees
- SPFI N/A
- MYGN N/A
- Industry
- SPFI Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SPFI Finance
- MYGN Health Care
- Exchange
- SPFI Nasdaq
- MYGN Nasdaq
- Market Cap
- SPFI 662.8M
- MYGN 642.0M
- IPO Year
- SPFI 2019
- MYGN 1995
- Fundamental
- Price
- SPFI $38.28
- MYGN $7.58
- Analyst Decision
- SPFI Buy
- MYGN Hold
- Analyst Count
- SPFI 3
- MYGN 13
- Target Price
- SPFI $41.67
- MYGN $13.50
- AVG Volume (30 Days)
- SPFI 51.4K
- MYGN 1.5M
- Earning Date
- SPFI 10-22-2025
- MYGN 11-06-2025
- Dividend Yield
- SPFI 1.56%
- MYGN N/A
- EPS Growth
- SPFI 19.09
- MYGN N/A
- EPS
- SPFI 3.20
- MYGN N/A
- Revenue
- SPFI $199,001,000.00
- MYGN $832,900,000.00
- Revenue This Year
- SPFI $13.41
- MYGN $0.17
- Revenue Next Year
- SPFI $6.10
- MYGN $6.19
- P/E Ratio
- SPFI $12.03
- MYGN N/A
- Revenue Growth
- SPFI 7.49
- MYGN 3.83
- 52 Week Low
- SPFI $30.01
- MYGN $3.76
- 52 Week High
- SPFI $42.38
- MYGN $26.60
- Technical
- Relative Strength Index (RSI)
- SPFI 42.61
- MYGN 55.60
- Support Level
- SPFI $37.65
- MYGN $7.04
- Resistance Level
- SPFI $39.59
- MYGN $8.25
- Average True Range (ATR)
- SPFI 1.15
- MYGN 0.38
- MACD
- SPFI -0.14
- MYGN -0.05
- Stochastic Oscillator
- SPFI 18.83
- MYGN 45.74
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.